Literature DB >> 22588626

Cardiac β-adrenergic receptor density and myocardial systolic function in the remote noninfarcted region after prior myocardial infarction with left ventricular remodelling.

Nobuyuki Ohte1, Hitomi Narita, Akihiko Iida, Hidekatsu Fukuta, Narushi Iizuka, Junichiro Hayano, Yuji Kuge, Nagara Tamaki, Genjiro Kimura.   

Abstract

PURPOSE: After myocardial infarction (MI), left ventricular (LV) remodelling is observed in noninfarcted LV myocardium. LV remodelling is closely associated with systolic heart failure. Since myocardial dysfunction is related to the downregulation of cardiac postsynaptic beta-adrenergic receptors (β-AR), we hypothesized that a reduction in β-AR density may be manifested in the remote noninfarcted region and such reduction may be related to myocardial systolic dysfunction. Accordingly, we assessed β-AR density with a focus on the remote noninfarcted region.
METHODS: Cardiac PET was performed in 15 patients with a prior MI and 10 age-matched healthy controls using (11)C-CGP 12177, a radioligand for β-receptors. The maximum number of available specific (11)C-CGP 12177 binding sites per gram of tissue was calculated in regions of interest using an established graphical method. LV regional systolic function was assessed based on peak systolic myocardial strain on the LV wall in the longitudinal direction using two-dimensional ultrasound speckle tracking imaging. LV volumes and LV ejection fraction (EF) were also measured.
RESULTS: The LV end-diastolic volume index was significantly larger in patients than in controls (67.8 ± 16.9 vs. 49.1 ± 12.3 ml/m(2), p < 0.01). Significant differences in β-AR density were observed among three areas: the apical area in controls (where the lowest β-AR density was observed), the remote noninfarcted region of patients and LVEF ≥ 55 %, and the remote noninfarcted region of patients and LVEF <55 % (5.8 ± 2.1 vs. 4.2 ± 0.7 vs. 3.3 ± 0.7 pmol/ml, p < 0.01, ANOVA). Peak systolic myocardial strain was significantly reduced in the remote noninfarcted LV wall in patients with a prior anterior wall MI compared with that in the corresponding wall in controls (-15.5 ± 2.5 vs. -20.1 ± 2.2 %, p < 0.001). A similar finding was also observed in patients with a prior inferior wall MI.
CONCLUSION: In the remote noninfarcted region in patients, β-AR downregulation was observed, which was related to deterioration of local myocardial systolic function.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22588626     DOI: 10.1007/s00259-012-2138-4

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  30 in total

1.  Myocardial oxidative metabolism in remote normal regions in the left ventricles with remodeling after myocardial infarction: effect of beta-adrenoceptor blockers.

Authors:  Nobuyuki Ohte; Kazuyuki Kurokawa; Akihiko Iida; Hitomi Narita; Sachie Akita; Kazuhiro Yajima; Hiromichi Miyabe; Junichiro Hayano; Genjiro Kimura
Journal:  J Nucl Med       Date:  2002-06       Impact factor: 10.057

2.  Evaluation of whole left ventricular systolic performance and local myocardial systolic function in patients with prior myocardial infarction using global long-axis myocardial strain.

Authors:  Nobuyuki Ohte; Hitomi Narita; Hiromichi Miyabe; Norio Takada; Toshihiko Goto; Hiroumi Mizuno; Kaoru Asada; Junichiro Hayano; Genjiro Kimura
Journal:  Am J Cardiol       Date:  2004-10-01       Impact factor: 2.778

3.  Noninvasive myocardial strain measurement by speckle tracking echocardiography: validation against sonomicrometry and tagged magnetic resonance imaging.

Authors:  Brage H Amundsen; Thomas Helle-Valle; Thor Edvardsen; Hans Torp; Jonas Crosby; Erik Lyseggen; Asbjørn Støylen; Halfdan Ihlen; João A C Lima; Otto A Smiseth; Stig A Slørdahl
Journal:  J Am Coll Cardiol       Date:  2006-01-26       Impact factor: 24.094

4.  Impaired myocardial oxidative metabolism in the remote normal region in patients in the chronic phase of myocardial infarction and left ventricular remodeling.

Authors:  Nobuyuki Ohte; Hitomi Narita; Akihiko Iida; Kazuaki Wakami; Kaoru Asada; Hidekatsu Fukuta; Takafumi Kato; Junichiro Hyano; Genjiro Kimura
Journal:  J Nucl Cardiol       Date:  2009-01-20       Impact factor: 5.952

5.  Homogeneously reduced versus regionally impaired myocardial blood flow in hypertensive patients: two different patterns of myocardial perfusion associated with degree of hypertrophy.

Authors:  A Gimelli; J Schneider-Eicke; D Neglia; G Sambuceti; A Giorgetti; G Bigalli; G Parodi; R Pedrinelli; O Parodi
Journal:  J Am Coll Cardiol       Date:  1998-02       Impact factor: 24.094

Review 6.  Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms.

Authors:  N B Schiller; P M Shah; M Crawford; A DeMaria; R Devereux; H Feigenbaum; H Gutgesell; N Reichek; D Sahn; I Schnittger
Journal:  J Am Soc Echocardiogr       Date:  1989 Sep-Oct       Impact factor: 5.251

7.  p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload.

Authors:  Masanori Sano; Tohru Minamino; Haruhiro Toko; Hideyuki Miyauchi; Masayuki Orimo; Yingjie Qin; Hiroshi Akazawa; Kaoru Tateno; Yosuke Kayama; Mutsuo Harada; Ippei Shimizu; Takayuki Asahara; Hirofumi Hamada; Shuhei Tomita; Jeffrey D Molkentin; Yunzeng Zou; Issei Komuro
Journal:  Nature       Date:  2007-03-04       Impact factor: 49.962

8.  B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure.

Authors:  Yoshitaka Iwanaga; Isao Nishi; Shinichi Furuichi; Teruo Noguchi; Kazuhiro Sase; Yasuki Kihara; Yoichi Goto; Hiroshi Nonogi
Journal:  J Am Coll Cardiol       Date:  2006-01-26       Impact factor: 24.094

9.  Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts.

Authors:  M R Bristow; R Ginsburg; W Minobe; R S Cubicciotti; W S Sageman; K Lurie; M E Billingham; D C Harrison; E B Stinson
Journal:  N Engl J Med       Date:  1982-07-22       Impact factor: 91.245

10.  Myocardial beta-adrenergic receptor density assessed by 11C-CGP12177 PET predicts improvement of cardiac function after carvedilol treatment in patients with idiopathic dilated cardiomyopathy.

Authors:  Masanao Naya; Takahiro Tsukamoto; Koichi Morita; Chietsugu Katoh; Kenichi Nishijima; Hiroshi Komatsu; Satoshi Yamada; Yuji Kuge; Nagara Tamaki; Hiroyuki Tsutsui
Journal:  J Nucl Med       Date:  2009-01-21       Impact factor: 10.057

View more
  5 in total

Review 1.  Recent Advances and Clinical Applications of PET Cardiac Autonomic Nervous System Imaging.

Authors:  Nabil E Boutagy; Albert J Sinusas
Journal:  Curr Cardiol Rep       Date:  2017-04       Impact factor: 2.931

2.  Preclinical characterization of a novel radiolabeled analog of practolol for the molecular imaging of myocardial β-adrenoceptor density.

Authors:  Eric Carbonnelle; Véronique Josserand; Laurent M Riou; Olivier Ormezzano; Alexis Broisat; Pascale Perret; Gilles Barone-Rochette; Daniel Fagret; Catherine Ghezzi
Journal:  J Nucl Cardiol       Date:  2014-05-30       Impact factor: 5.952

3.  (-)-Epigallocatechin-3-gallate, the major green tea catechin, regulates the desensitization of β1 adrenoceptor via GRK2 in experimental heart failure.

Authors:  Qi Zhang; Liqun Hu; Li Chen; Hongqi Li; Jun Wu; Wenting Liu; Mengyuan Zhang; Guang Yan
Journal:  Inflammopharmacology       Date:  2017-12-16       Impact factor: 4.473

Review 4.  Assessment of cardiac autonomic neuronal function using PET imaging.

Authors:  James T Thackeray; Frank M Bengel
Journal:  J Nucl Cardiol       Date:  2013-02       Impact factor: 5.952

5.  Downregulation of β-Adrenoceptors in Isoproterenol-Induced Cardiac Remodeling through HuR.

Authors:  Qian Yin; Chengzhi Yang; Jimin Wu; Haiyan Lu; Xiaohui Zheng; Youyi Zhang; Zhizhen Lv; Xiaopu Zheng; Zijian Li
Journal:  PLoS One       Date:  2016-04-01       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.